60964-09-2

Basic information

• Product Name: 2,6-DICHLORO-4-HYDROXYBENZALDEHYDE
• Synonyms: 2,6-Dichloro-4-hydroxybenzaldehyde;2,6-Dichloro-3-hydroxy-benzaldehyde
• CAS NO: 60964-09-2
• Molecular Formula: C₇H₄Cl₂O₂
• Molecular Weight: 191.01
• EINECS: 1312995-182-4
• Product Categories: Aromatic Aldehydes & Derivatives (substituted)
• Mol File: 60964-09-2.mol

Chemical Properties

• Melting Point: 227-229°C
• Boiling Point: 295.8 °C at 760 mmHg
• Flash Point: 132.7 °C
• Appearance: /
• Density: 1.547 g/cm³
• Vapor Pressure: 0.000844mmHg at 25°C
• Refractive Index: 1.643
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 5.87±0.23(Predicted)
• Water Solubility: Insoluble in water.
• Sensitive: Air Sensitive
• CAS DataBase Reference: 2,6-DICHLORO-4-HYDROXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLORO-4-HYDROXYBENZALDEHYDE(60964-09-2)
• EPA Substance Registry System: 2,6-DICHLORO-4-HYDROXYBENZALDEHYDE(60964-09-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 60964-09-2(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
2,6-Dichloro-4-hydroxybenzaldehyde is used as a starting reagent in the synthesis of various organic compounds. Its unique structure and reactivity make it a valuable precursor for the production of a wide range of chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2,6-Dichloro-4-hydroxybenzaldehyde is used as a starting material for the synthesis of various drug candidates. Its versatility in chemical reactions allows for the development of new and innovative therapeutic agents.
Used in Agrochemical Industry:
2,6-Dichloro-4-hydroxybenzaldehyde is also utilized in the agrochemical industry as a starting reagent for the synthesis of various agrochemical products, such as pesticides and herbicides. Its ability to undergo a range of chemical reactions makes it a valuable component in the development of these products.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 2,6-Dichloro-4-hydroxybenzaldehyde is used as a starting material for the synthesis of various dyes and pigments. Its unique chemical structure contributes to the color and properties of the final products.
Used in Research and Development:
2,6-Dichloro-4-hydroxybenzaldehyde is employed in research and development settings as a versatile compound for exploring new chemical reactions and syntheses. Its reactivity and availability make it an attractive candidate for scientific investigations and the development of new chemical processes.

InChI:InChI=1/C7H4Cl2O2/c8-6-1-4(11)2-7(9)5(6)3-10/h1-3,11H

Upstream product

• 67-66-3 chloroform 
• 591-35-5 3,5-dichlorophenol 
• 126663-61-4 1-<(tert-butyldimethylsilyl)oxy>-3,5-dichlorobenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 82772-93-8 2,6-dichloro-4-methoxy-benzaldehyde 
• 616195-93-8 2,6-dichloro-4-triisopropylsilyloxy-benzaldehyde 
• 216257-25-9 3-chloro-5-[(triisopropylsilyl)oxy]phenyl chloride 
• 33719-74-3 3,5-dichloroanisole 
• 86111-47-9 (2,6-dichloro-4-methoxy-phenyl)-methanol 

Downstream Products

• 461031-79-8 4-(benzyloxy)-2,6-dichlorobenzaldehyde 
• 634192-53-3 3,5-dichloro-4-formyl-phenyl trifluoromethanesulfonate 
• 873111-12-7 2,6-dichloro-4-(2-phthalimidoethoxy)benzaldehyde 
• 873111-49-0 5-[2,6-dichloro-4-(chloroacetoxy)phenyl]dipyrromethane 
• 873111-13-8 5-[2,6-dichloro-4-(2-phthalimidoethoxy)phenyl]dipyrromethane 
• 616195-97-2 methyl 2-(3,5-dichloro-4-formylphenoxy)acetate 
• 616196-07-7 2,6-dichloro-4-(2-hydroxyethoxy)benzaldehyde 
• 616196-01-1 (rac)-2,6-dichloro-4-(2,2-dimethyl-[1,3]-dioxolane-4-ylmethoxy) benzaldehyde 
• 616196-22-6 2,6-dichloro-4-[3-((tert-butyldimethylsilanyloxy))-2-(tert-butyldimethylsilanyloxymethyl)-propoxy)-benzaldehyde 
• 1200131-10-7 3,5-dichloro-4-piperidin-1-ylmethylphenol 
• 1207463-42-0 (5-[5-(3,5-dichloro-4-formylphenyloxy)-pentylcarbamoyl]-pentyl)-carbamic acid tert-butyl ester 
• 84746-48-5 (E)-2-(2,6-dichloro-4-hydroxybenzylidene)hydrazinecarboximidamide 
• 1416975-45-5 2,6-dichloro-4-(2-methoxyethoxy)benzoic acid 
• 720679-54-9 3,5-dichloro-4-(hydroxymethyl)phenol 

Relevant articles and documents

2-(2-ACRYLOYL-2,6-DIAZASPIRO[3.4]OCTAN-6-YL)-6-(1H-INDAZOL-4-YL)-BENZONITRILE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF G12C MUTANT KRAS PROTEIN FOR INHIBITING TUMOR METASTASIS

The present invention provides e.g. 2-(2-acryloyl-2,6- diazaspiro[3.4]octan-6-yl)-6-(lH-indazol-4-yl)-benzonitrile and e.g. 2-(2-acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-6-(1H-indazol-4-yl)- benzonitrile derivatives and related compounds of formula (I) as inhibitors of G12C mutant KRAS protein for treating tumor metastasis. The present description discloses exemplary compounds (e.g. pages 53 to 90; table 1; compounds I-1 to I-141), pharmacological data (e.g. page 125 to 128; table 2; example 1) and synthesis thereof (e.g. pages 129 to 143; examples 2 to 7). Exemplary compounds are e.g. 2-(2-acryloyl-2,6- diazaspiro[3.4]octan-6-yl)-6-(5-methyl-1H-indazol-4-yl)-4- morpholinobenzonitrile (example 2; compound I-1) and 6-(2- acryloyl-2,7-diazaspiro[3.5]nonan-7-yl)-3-methoxy-2-(5-methyl-1H- indazol-4-yl)-4-morpholinobenzonitrile (example 7; compound I-84).

NOVEL THYROMIMETICS

Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function as thyromimetics and have utility for treating diseases such as neurodegenerative disorders and fibrotic diseases. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation.

DERIVATIVES OF SOBETIROME

Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

DERIVATIVES OF SOBETIROME

Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative dis

Increasing Thyromimetic Potency through Halogen Substitution

Sobetirome is one of the most studied thyroid hormone receptor β (TRβ)-selective thyromimetics in the field due to its excellent selectivity and potency. A small structural change—replacing the 3,5-dimethyl groups of sobetirome with either chlorine or bro

CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compound

OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS

The present invention provides oxadiazolyl- substituted benzimidazole- and idole-derivates that are useful for treating conditions or disorders associated with DGAT1 activity in animals, particularly humans.

TETRACYCLIC INHIBITORS OF JANUS KINASES

The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity.

PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1

ABSTRACT The present invention discloses novel compounds of Formula I: ( I ) having 11-Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11-Beta-HSD type 1 activity. X-17433 PCT -1-